Trial · NCT02048215
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in resting energy expenditure | Baseline and 1 month | Resting energy expenditure is measured by indirect calorimetry |
| Secondary | Blood pressure monitoring | Baseline and daily for 30 days (t.i.d.) | |
| Secondary | Electrocardiograpic monitoring | Baseline and at week 2,3,4 | |
| Secondary | Cardiac ultrasound monitoring | Baseline and at week 2,3,4 | Cardiac ultrasound measurement for assessing possible detrimental changes |
| Secondary | Changes in fasting glucose | Baseline and at one month | Patients are assessed by oral glucose tolerance test at baseline and following one month of treatment, with assessment of glucose, insulin, free-fatty acids and glycerol |
| Secondary | Changes in fasting insulin | baseline and one month | Patients are assessed by oral glucose tolerance test at baseline and following one month of treatment, with assessment of glucose, insulin, free-fatty acids and glycerol |
| Secondary | Changes in fasting free fatty acids | baseline ans one month | Patients are assessed by oral glucose tolerance test at baseline and following one month of treatment, with assessment of glucose, insulin, free-fatty acids and glycerol |
| Secondary | Changes in fasting glycerol | baseine and one month | Patients are assessed by oral glucose tolerance test at baseline and following one month of treatment, with assessment of glucose, insulin, free-fatty acids and glycerol |
| Secondary | Changes in thyroid function (TSH, T3, T4) | Baseline and 1 month | |
| Secondary | Changes in plasma noradrenalin | Baseline and 1 month | |
| Secondary | Changes in body weight | baseline and 1 month | |
| Secondary | Beta-3 adrenoceptor expression in human adipose tissue | one month | Beta-3 adrenoceptor expression is measured in subcutaneous and omental tissue sampled during bariatric surgery following one month of pharmacological intervention |
| Secondary | UCP-3 expression in human muscle tissue | One month | UCP-3 expression is measured in rectus abdominis muscle tissue sampled during bariatric surgery following one month of pharmacological intervention |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02048215/registered